Amgen (AMGN) EBITDA (2009 - 2026)

Amgen has reported EBITDA for 18 years, with the latest figure at $3.5 billion in Q2 2026.

• On a quarterly basis, EBITDA rose 32.3% year-over-year to $3.5 billion in Q2 2026; TTM through Jun 2026 was $11.4 billion, a 39.48% increase from a year earlier, with the FY2025 full-year figure at $9.1 billion, up 25.1% from the prior year.
• EBITDA was $3.5 billion for Q2 2026 at Amgen, up from $2.7 billion in the prior quarter.
• The five-year high for EBITDA was $3.5 billion in Q2 2026, with the low at $991.0 million in Q1 2024.
• Average EBITDA over 5 years is $2.2 billion, with a median of $2.3 billion recorded in 2022.
• The sharpest annual moves came in 2022 and 2024: EBITDA surged 162.8% in 2022, then slumped 48.41% in 2024.
• Over 5 years, EBITDA stood at $2.2 billion in 2022, then plunged by 43.0% to $1.3 billion in 2023, then jumped by 81.83% to $2.3 billion in 2024, then gained by 17.7% to $2.7 billion in 2025, then advanced by 29.19% to $3.5 billion in 2026.
• The last three EBITDA figures came in at $3.5 billion (Q2 2026), $2.7 billion (Q1 2026), and $2.7 billion (Q4 2025), per Business Quant data.